IPF Collaboration Potential Simcere's ongoing research collaborations with Stanford Medicine to advance idiopathic pulmonary fibrosis therapies position the company as a strong partner for joint development, licensing, or co-commercialization of IPF assets in global markets. BD teams can explore exclusive regional rights, early access manufacturing, and milestone-based collaboration structures to accelerate IPF programs.

Oncology Innovation With an active oncology portfolio and exposure at major conferences like ASCO, Simcere offers opportunities for ADC development partnerships, asset licensing, and contract manufacturing of advanced oncology candidates. Potential sales angles include clinical trial material supply, late-stage manufacturing, and co-promotion arrangements in select markets.

China Commercial Strength Simcere has launched multiple branded therapies in China and built a robust domestic commercialization platform, enabling partnerships to distribute new drugs in China, access hospital channels, and navigate local regulatory processes for foreign assets entering the Chinese market.

Strategic Partnerships The company emphasizes strategic cooperation with innovative companies and research institutes, creating ready-made paths for joint ventures, research collaborations, and asset-sharing deals spanning Neuroscience, Autoimmune, Infections, and Oncology to accelerate portfolio expansion.

Global Access Capabilities Simcere's collaboration footprint and R&D orientation position it to assist global sponsors with China entry, regulatory alignment, tech transfer, and end-to-end clinical supply chain support, enabling efficient market access and scale for partner assets.